A citation-based method for searching scientific literature

Pravin U Dugel, Adrian Koh, Yuichiro Ogura, Glenn J Jaffe, Ursula Schmidt-Erfurth, David M Brown, Andre V Gomes, James Warburton, Andreas Weichselberger, Frank G Holz. Ophthalmology 2020
Times Cited: 272







List of co-cited articles
570 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Pravin U Dugel, Rishi P Singh, Adrian Koh, Yuichiro Ogura, Georges Weissgerber, Kinfemichael Gedif, Glenn J Jaffe, Ramin Tadayoni, Ursula Schmidt-Erfurth, Frank G Holz. Ophthalmology 2021
80
41

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S Heier, David M Brown, Victor Chong, Jean-Francois Korobelnik, Peter K Kaiser, Quan Dong Nguyen, Bernd Kirchhof, Allen Ho, Yuichiro Ogura, George D Yancopoulos,[...]. Ophthalmology 2012
31

Ranibizumab for neovascular age-related macular degeneration.
Philip J Rosenfeld, David M Brown, Jeffrey S Heier, David S Boyer, Peter K Kaiser, Carol Y Chung, Robert Y Kim. N Engl J Med 2006
25

Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Caroline R Baumal, Richard F Spaide, Lejla Vajzovic, K Bailey Freund, Scott D Walter, Vishak John, Ryan Rich, Nauman Chaudhry, Rohit R Lakhanpal, Patrick R Oellers,[...]. Ophthalmology 2020
96
26

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Jordi Monés, Sunil K Srivastava, Glenn J Jaffe, Ramin Tadayoni, Thomas A Albini, Peter K Kaiser, Frank G Holz, Jean-Francois Korobelnik, Ivana K Kim, Christian Pruente,[...]. Ophthalmology 2021
69
36

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.
Sara J Haug, Doan Luong Hien, Gunay Uludag, Than Trong Tuong Ngoc, Sherin Lajevardi, M Sohail Halim, Yasir J Sepah, Diana V Do, Arshad M Khanani. Am J Ophthalmol Case Rep 2020
61
34

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
Daniel F Martin, Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald, Stuart L Fine, Glenn J Jaffe. N Engl J Med 2011
21

Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Quan Dong Nguyen, Arup Das, Diana V Do, Pravin U Dugel, Andre Gomes, Frank G Holz, Adrian Koh, Carolyn K Pan, Yasir J Sepah, Nikhil Patel,[...]. Ophthalmology 2020
65
32

Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.
Andre J Witkin, Paul Hahn, Timothy G Murray, J Fernando Arevalo, Kevin J Blinder, Netan Choudhry, Geoff G Emerson, Roger A Goldberg, Stephen J Kim, Joel Pearlman,[...]. J Vitreoretin Dis 2020
65
29

Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.
Frank G Holz, Pravin U Dugel, Georges Weissgerber, Robin Hamilton, Rufino Silva, Francesco Bandello, Michael Larsen, Andreas Weichselberger, Andreas Wenzel, Anne Schmidt,[...]. Ophthalmology 2016
69
26

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).
Ursula Schmidt-Erfurth, Victor Chong, Anat Loewenstein, Michael Larsen, Eric Souied, Reinier Schlingemann, Bora Eldem, Jordi Monés, Gisbert Richard, Francesco Bandello. Br J Ophthalmol 2014
308
16

Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.
Atul Jain, Sophaktra Chea, Wataru Matsumiya, M Sohail Halim, Çigdem Yaşar, Guoping Kuang, Yasir J Sepah, Arshad M Khanani, Diana V Do, Quan Dong Nguyen. Am J Ophthalmol Case Rep 2020
45
35

Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.
Caroline R Baumal, Bahram Bodaghi, Michael Singer, David J Tanzer, András Seres, Mayur R Joshi, Nicolas Feltgen, Richard Gale. Ophthalmol Retina 2021
38
42

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Ursula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, David M Brown, Victor Chong, Quan Dong Nguyen, Allen C Ho, Yuichiro Ogura, Christian Simader, Glenn J Jaffe,[...]. Ophthalmology 2014
521
15

Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Pravin U Dugel, Glenn J Jaffe, Peter Sallstig, James Warburton, Andreas Weichselberger, Mark Wieland, Lawrence Singerman. Ophthalmology 2017
119
15

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
David M Brown, Peter K Kaiser, Mark Michels, Gisele Soubrane, Jeffrey S Heier, Robert Y Kim, Judy P Sy, Susan Schneider. N Engl J Med 2006
15

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Robyn H Guymer, Caroline M Markey, Ian L McAllister, Mark C Gillies, Alex P Hunyor, Jennifer J Arnold. Ophthalmology 2019
132
15

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group.
Richard F Spaide, Glenn J Jaffe, David Sarraf, K Bailey Freund, Srinivas R Sadda, Giovanni Staurenghi, Nadia K Waheed, Usha Chakravarthy, Philip J Rosenfeld, Frank G Holz,[...]. Ophthalmology 2020
169
14


Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan Ling Wong, Xinyi Su, Xiang Li, Chui Ming G Cheung, Ronald Klein, Ching-Yu Cheng, Tien Yin Wong. Lancet Glob Health 2014
13

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration.
Frank G Holz, Ramin Tadayoni, Stephen Beatty, Alan Berger, Matteo G Cereda, Rafael Cortez, Carel B Hoyng, Philip Hykin, Giovanni Staurenghi, Stephanie Heldner,[...]. Br J Ophthalmol 2015
340
12

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.
Maureen G Maguire, Daniel F Martin, Gui-Shuang Ying, Glenn J Jaffe, Ebenezer Daniel, Juan E Grunwald, Cynthia A Toth, Frederick L Ferris, Stuart L Fine. Ophthalmology 2016
374
11

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Brandon G Busbee, Allen C Ho, David M Brown, Jeffrey S Heier, Ivan J Suñer, Zhengrong Li, Roman G Rubio, Phillip Lai. Ophthalmology 2013
339
11

Brolucizumab-early real-world experience: BREW study.
Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Srinivas R Sadda, Giulia Corradetti, Jeffrey Heier, Adam T Chin, David Boyer, Pouya Dayani, Sruthi Arepalli,[...]. Eye (Lond) 2021
22
50

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
Rufino Silva, András Berta, Michael Larsen, Wayne Macfadden, Chrystel Feller, Jordi Monés. Ophthalmology 2018
140
11

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
Soraya Rofagha, Robert B Bhisitkul, David S Boyer, SriniVas R Sadda, Kang Zhang. Ophthalmology 2013
649
10

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.
Derek Kunimoto, Young Hee Yoon, Charles C Wykoff, Andrew Chang, Rahul N Khurana, Raj K Maturi, Hansjürgen Agostini, Eric Souied, David R Chow, Andrew J Lotery,[...]. Ophthalmology 2020
37
27

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
Charles C Wykoff, Daniel E Croft, David M Brown, Rui Wang, John F Payne, Lloyd Clark, Nizar Saleh Abdelfattah, SriniVas R Sadda. Ophthalmology 2015
180
9

A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.
Ursula Schmidt-Erfurth, Sebastian M Waldstein. Prog Retin Eye Res 2016
175
9

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.
Daniel F Martin, Maureen G Maguire, Stuart L Fine, Gui-shuang Ying, Glenn J Jaffe, Juan E Grunwald, Cynthia Toth, Maryann Redford, Frederick L Ferris. Ophthalmology 2012
9

Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Ursula Schmidt-Erfurth, Sebastian M Waldstein, Gabor-Gyoergy Deak, Michael Kundi, Christian Simader. Ophthalmology 2015
128
9

Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
Rebecca N Evans, Barnaby C Reeves, Maureen G Maguire, Daniel F Martin, Alyson Muldrew, Tunde Peto, Chris Rogers, Usha Chakravarthy. JAMA Ophthalmol 2020
36
25

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
Peter A Campochiaro, Dennis M Marcus, Carl C Awh, Carl Regillo, Anthony P Adamis, Vladimir Bantseev, Yawen Chiang, Jason S Ehrlich, Signe Erickson, William D Hanley,[...]. Ophthalmology 2019
113
9

Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study.
Jonathan L Prenner, Lawrence S Halperin, Catherine Rycroft, Susan Hogue, Zinaria Williams Liu, Robert Seibert. Am J Ophthalmol 2015
79
11


Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
Louisa Maria Bulirsch, Marlene Saßmannshausen, Jennifer Nadal, Raffael Liegl, Sarah Thiele, Frank G Holz. Br J Ophthalmol 2021
21
42

Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Ana Bety Enríquez, Caroline R Baumal, Ashley M Crane, Andre J Witkin, David R Lally, Michelle C Liang, José Ramón Enríquez, David A Eichenbaum. JAMA Ophthalmol 2021
20
45

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Sarah Wordsworth, Barnaby C Reeves. Ophthalmology 2012
585
8

Brolucizumab: First Approval.
Anthony Markham. Drugs 2019
39
20

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sumit Sharma, Cynthia A Toth, Ebenezer Daniel, Juan E Grunwald, Maureen G Maguire, Gui-Shuang Ying, Jiayan Huang, Daniel F Martin, Glenn J Jaffe. Ophthalmology 2016
132
8

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Jayashree Sahni, Sunil S Patel, Pravin U Dugel, Arshad M Khanani, Chirag D Jhaveri, Charles C Wykoff, Vrinda S Hershberger, Meike Pauly-Evers, Shamil Sadikhov, Piotr Szczesny,[...]. Ophthalmology 2019
82
8

Innovative therapies for neovascular age-related macular degeneration.
Hasenin Al-Khersan, Rehan M Hussain, Thomas A Ciulla, Pravin U Dugel. Expert Opin Pharmacother 2019
45
15

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
Glenn J Jaffe, Daniel F Martin, Cynthia A Toth, Ebenezer Daniel, Maureen G Maguire, Gui-Shuang Ying, Juan E Grunwald, Jiayan Huang. Ophthalmology 2013
175
6

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Allen C Ho, Brandon G Busbee, Carl D Regillo, Mark R Wieland, Sherri A Van Everen, Zhengrong Li, Roman G Rubio, Phillip Lai. Ophthalmology 2014
210
6

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
David M Brown, Mark Michels, Peter K Kaiser, Jeffrey S Heier, Judy P Sy, Tsontcho Ianchulev. Ophthalmology 2009
950
6

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Mark C Gillies, Alex P Hunyor, Jennifer J Arnold, Robyn H Guymer, Sebastian Wolf, Paul Ng, Francois L Pecheur, Ian L McAllister. JAMA Ophthalmol 2019
64
9


Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.
Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Lucy A Culliford, Barnaby C Reeves. Lancet 2013
508
6

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.
Nicholas Papadopoulos, Joel Martin, Qin Ruan, Ashique Rafique, Michael P Rosconi, Ergang Shi, Erica A Pyles, George D Yancopoulos, Neil Stahl, Stanley J Wiegand. Angiogenesis 2012
639
6

VEGF-Trap: a VEGF blocker with potent antitumor effects.
Jocelyn Holash, Sam Davis, Nick Papadopoulos, Susan D Croll, Lillian Ho, Michelle Russell, Patricia Boland, Ray Leidich, Donna Hylton, Elena Burova,[...]. Proc Natl Acad Sci U S A 2002
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.